Predictive Oncology (POAI) 10-Q 15 May 18 2018 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2018	May 12, 2018
Document Information [Line Items]
Entity Registrant Name	Precision Therapeutics Inc.
Entity Central Index Key	1,446,159
Trading Symbol	aipt
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		11,804,073
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Current Assets:
Cash and Cash Equivalents	$ 2,232,803	$ 766,189
Certificates of Deposit		244,971
Accounts Receivable	241,764	137,499
Notes Receivable	167,512	667,512
Inventories	272,556	265,045
Prepaid Expense and other assets	208,305	289,966
Total Current Assets	3,122,940	2,371,182
Notes Receivable	1,112,524	1,070,000
Investment in Subsidiary	1,542,250
Fixed Assets, net	106,009	87,716
Intangibles, net	115,714	95,356
Total Assets	5,999,437	3,624,254
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts Payable	186,309	140,462
Accrued Expenses	558,439	785,215
Deferred Revenue	38,856	6,663
Total Liabilities	783,604	932,340
Commitments and Contingencies
Stockholders’ Equity:
Common Stock, $.01 par value, 50,000,000 authorized, 11,804,073 and 6,943,283 outstanding	118,040	69,432
Additional paid-in capital	(61,622,067)	(57,380,256)
Accumulated Deficit	56,525,066	54,765,045
Total Stockholders' Equity	5,215,833	2,691,914
Total Liabilities and Stockholders' Equity	5,999,437	3,624,254
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity:
Convertible Preferred Stock	792	792
Series C Convertible Preferred Stock [Member]
Stockholders’ Equity:
Convertible Preferred Stock		$ 6,479

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares outstanding (in shares)	11,804,073	6,943,283
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	79,246	79,246
Series C Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	0	647,819

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Other Comprehensive Income (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue	$ 411,593	$ 175,166
Cost of goods sold	117,343	36,992
Gross margin	294,250	138,174
General and administrative expense	1,216,144	1,132,073
Operations expense	287,590	200,494
Sales and marketing expense	550,538	147,454
Total Expense	2,054,272	1,480,021
Net loss attributable to common shareholders	(1,760,022)	(1,341,847)
Comprehensive loss	$ (1,760,022)	$ (1,341,847)
Loss per common share - basic and diluted (in dollars per share)	$ (0.15)	$ (0.21)
Weighted average shares used in computation - basic and diluted (in shares)	11,383,217	6,450,967

Statement of Stockholders' Equi

Statement of Stockholders' Equity (Unaudited) - USD ($)	Over-Allotment Option [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Over-Allotment Option [Member]Preferred Stock [Member]	Over-Allotment Option [Member]Common Stock [Member]	Over-Allotment Option [Member]Additional Paid-in Capital [Member]	Over-Allotment Option [Member]Retained Earnings [Member]	Over-Allotment Option [Member]AOCI Attributable to Parent [Member]	Over-Allotment Option [Member]	Consulting Agreement One [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Consulting Agreement One [Member]Preferred Stock [Member]	Consulting Agreement One [Member]Common Stock [Member]	Consulting Agreement One [Member]Additional Paid-in Capital [Member]	Consulting Agreement One [Member]Retained Earnings [Member]	Consulting Agreement One [Member]AOCI Attributable to Parent [Member]	Consulting Agreement One [Member]	Consulting Agreement Two [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Consulting Agreement Two [Member]Preferred Stock [Member]	Consulting Agreement Two [Member]Common Stock [Member]	Consulting Agreement Two [Member]Additional Paid-in Capital [Member]	Consulting Agreement Two [Member]Retained Earnings [Member]	Consulting Agreement Two [Member]AOCI Attributable to Parent [Member]	Consulting Agreement Two [Member]	Private Placement [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Private Placement [Member]Preferred Stock [Member]	Private Placement [Member]Common Stock [Member]	Private Placement [Member]Additional Paid-in Capital [Member]	Private Placement [Member]Retained Earnings [Member]	Private Placement [Member]AOCI Attributable to Parent [Member]	Private Placement [Member]	Helomics Holding Corp. [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Helomics Holding Corp. [Member]Preferred Stock [Member]	Helomics Holding Corp. [Member]Common Stock [Member]	Helomics Holding Corp. [Member]Additional Paid-in Capital [Member]	Helomics Holding Corp. [Member]Retained Earnings [Member]	Helomics Holding Corp. [Member]AOCI Attributable to Parent [Member]	Helomics Holding Corp. [Member]	Investor Relations Consultant [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Investor Relations Consultant [Member]Preferred Stock [Member]	Investor Relations Consultant [Member]Common Stock [Member]	Investor Relations Consultant [Member]Additional Paid-in Capital [Member]	Investor Relations Consultant [Member]Retained Earnings [Member]	Investor Relations Consultant [Member]AOCI Attributable to Parent [Member]	Investor Relations Consultant [Member]	Series E Warrants [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Series E Warrants [Member]Preferred Stock [Member]	Series E Warrants [Member]Common Stock [Member]	Series E Warrants [Member]Additional Paid-in Capital [Member]	Series E Warrants [Member]Retained Earnings [Member]	Series E Warrants [Member]AOCI Attributable to Parent [Member]	Series E Warrants [Member]	Preferred Stock [Member]Series C Preferred Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2016																																																				4,564,428
Balance at Dec. 31, 2016																																																			$ 792	$ 45,644	$ 47,894,196	$ (47,018,451)	$ 1,501	$ 923,682
Shares issued pursuant to the public offering, net (in shares)			175,000																			1,213,819																														1,750,000
Shares issued pursuant to the public offering, net			$ 1,750	$ 392,000			$ 393,750																$ 12,138		$ 1,201,681			$ 1,213,819																								$ 17,500	3,403,688			3,421,188
Vesting Expense																																																					4,042,256			4,042,256
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement (in shares)																																																				(400,000)
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement																																																				$ (4,000)				(4,000)
Shares issued for services (in shares)										100,000							43,333																					50,000
Shares issued for services										$ 1,000	$ 219,000			$ 220,000			$ 433	$ 63,699			$ 64,132																	$ 500	$ 78,500			$ 79,000
Unrealized (loss) from marketable securities																																																						(1)	(1,501)	(1,501)
Preferred conversion to common shares pursuant to a private placement agreement (in shares)																																																		(566,000)		660,522
Preferred conversion to common shares pursuant to a private placement agreement																																																			(5,659)	$ 6,604	85,236			86,182
Net loss																																																						(7,746,593)		(7,746,593)
Balance (in shares) at Dec. 31, 2017																																																		(647,819)		(6,943,283)
Balance at Dec. 31, 2017																																																			7,271	$ 69,432	57,380,256	(54,765,045)		2,691,914
Shares issued pursuant to the public offering, net (in shares)			215,247																																																	2,900,000
Shares issued pursuant to the public offering, net			$ 2,153	$ 202,268	$ 1		$ 204,422																																													$ 29,000	2,726,087			2,755,087
Vesting Expense																																																					226,387			226,387
Unrealized (loss) from marketable securities
Preferred conversion to common shares pursuant to a private placement agreement (in shares)																																																		(647,819)		589,747
Preferred conversion to common shares pursuant to a private placement agreement																																																			(6,479)	$ 5,897	582
Net loss																																																						(1,760,022)		(1,760,022)
Investment in subsidiary pursuant to Helomics 20% acquisition (in shares)																															1,100,000
Investment in subsidiary pursuant to Helomics 20% acquisition																															$ 11,000	$ 1,031,250			$ 1,042,250
E warrant exercises pursuant to S-3 public offering at $1.00 exercise price per share (in shares)																																													55,796
E warrant exercises pursuant to S-3 public offering at $1.00 exercise price per share																																													$ 558	$ 55,238			$ 55,796
Balance (in shares) at Mar. 31, 2018																																																				(11,804,073)
Balance at Mar. 31, 2018																																																			$ 792	$ 118,040	$ 61,622,067	$ (56,525,066)		$ 5,215,833

Statement of Stockholders' Equ6

Statement of Stockholders' Equity (Unaudited) (Parentheticals)	Dec. 31, 2017$ / shares
Investor Relations Consultant [Member]
Price of shares issued (in dollars per share)	$ 1.58
Shares Issued, Price Per Share	$ 1.58

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flow from operating activities:
Net loss	$ (1,760,022)	$ (1,341,847)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	18,167	18,574
Vested stock options and warrants	226,387	587,444
Loss from sale of marketable securities		(1,837)
Changes in assets and liabilities:
Accounts receivable	(104,265)	(29,587)
Inventories	(7,511)	23,022
Prepaid expense and other assets	81,661	(11,645)
Accounts payable	45,847	(140,848)
Accrued expenses	(226,775)	(265,893)
Deferred Revenue	32,193	6,409
Net cash used in operating activities:	(1,694,318)	(1,156,208)
Cash flow from investing activities:
Proceeds from sale of marketable securities		284,665
Purchase of certificates of deposit		(2,593,985)
Redemption of certificates of deposit	244,971
Advance on notes receivable	(42,524)
Purchase of fixed assets	(32,789)	(26,898)
Purchase of intangibles	(24,029)	(194)
Net cash provided by (used in) investing activities:	145,629	(2,336,412)
Cash flow from financing activities:
Proceeds from exercise of warrants into common stock	55,794
Issuance of common stock	2,959,509	3,814,938
Net cash provided by (used in) financing activities	3,015,303	3,814,938
Net increase in cash and cash equivalents	1,466,614	322,318
Cash at beginning of period	766,189	1,764,090
Cash at end of period	2,232,803	2,086,408
Non-cash transactions:
Conversion of Preferred Stock to Common Stock	6,479
Investment in Subsidiary	$ 1,542,250

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 1 Nature of Operations and Continuance of Operations Precision Therapeutics Inc., (the “Company”) was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. As of March 31, 2018, 11,804,073 $.01 In April 2009, 510 25% first The accompanying condensed consolidated financial statements (the “financial statements”) have been prepared assuming the Company will continue as a going concern. The Company has incurred recurring losses from operations and has an accumulated deficit of $56,525,066. $2,232,803 March 31, 2018 not Since inception to March 31, 2018, $35,840,380 1 $2,055,000 2 $13,555,003 3 $1,739,770 4 $3,937,500 $358,312 5 $1,300,000 6 $2,755,000 7 $5,685,000 Interim Financial Statements The Company has prepared the unaudited interim financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which in the opinion of management, are necessary to present fairly the Company’s position, the results of its operations and its cash flows for the interim periods. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Form 10 April 2, 2018. may not Recent Accounting Developments In May 2014, No. 2014 09, 606 January 1, 2018 not December 31, 2017. January 1, 2018 606, not 605, Revenue Recognition not December 31, 2017, not January 1, 2018. 2 In January 2016, No. 2016 01, Financial Instruments-Overall (Subtopic 825 10 2016 01” not not December 15, 2017, March 31, 2018, no In February 2016, No. 2016 02, Leases (Topic 842 2016 02” December 15, 2018. On December 22, 2017, 2017 34% 21%. The Company reviewed all other significant newly issued accounting pronouncements and determined they are either not no Valuation of Intangible Assets The Company reviews identifiable intangible assets for impairment annually, or whenever events or changes in circumstances indicate the carrying amount may not may not not Accounting Policies and Estimates The presentation of financial statements is in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Advertising Advertising costs are expensed as incurred. Advertising expenses were $4,394 three March 31, 2018 $4,271 three March 31, 2017. Research and Development Research and development costs are charged to operations as incurred. Research and development expenses were $94,011 three March 31, 2018 $84,472 three March 31, 2017. Cash Equivalents The Company considers all highly liquid debt instruments with a maturity of three Certificates of Deposit Short-term interest-bearing investments are those with maturities of less than one three one Fair Value Measurements Under generally accepted accounting principles as outlined in the FASB’s Accounting Standards Codification 820, 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities was determined based on Level 1 Inventories Inventories are stated at the lower of cost and net realizable value, with cost determined on a first first March 31, 2018 December 31, 2017 Finished goods $ 32,967 $ 62,932 Raw materials 183,216 141,028 Work-In-Process 56,373 61,085 Total $ 272,556 $ 265,045 Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing tooling 3 - 7 Demo equipment 3 The Company’s investment in fixed assets consists of the following: March 31, December 31, Computers and office equipment $ 190,484 $ 183,528 Leasehold improvements 41,397 25,635 Manufacturing tooling 108,955 108,955 Demo equipment 53,439 43,368 Total 394,275 361,486 Less: Accumulated depreciation 288,266 273,770 Total Fixed Assets, Net $ 106,009 $ 87,716 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Depreciation expense was $14,496 three March 31, 2018, $15,685 three March 31, 2017. Intangible Assets Intangible assets consist of trademarks and patent costs. Amortization expense was $3,671 three March 31, 2018, $2,888 three March 31, 2017. Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes 740” 740, There is no 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no Tax years subsequent to 2014 Patents and Intellectual Property On January 25, 2014, No. PCT/US2014/013081 61756763 one January 25, 2013. 148 The Company’s PCT patent application is for the new model of the surgical fluid waste management system. The Company obtained a favorable International Search Report from the PCT searching authority indicating that the claims in its PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facility’s sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 No. US20090216205 August 8, 2023. In July 2015, The United States Patent Office has assigned application #14/763,459 As of November 22, 2017, #14743665.3 1651, Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one $1,984,163 Segments The Company operates in two three March 31, 2018 2017 $26,662 2017 first March 2017. Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not

Note 2 - Revenue Recognition

Note 2 - Revenue Recognition	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	NOTE 2 Revenue from Product Sales The Company’s revenue consists primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. The Company sells its products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and the Terms and Conditions to be a customer’s contract in all cases. The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. The Company has elected the accounting policy to exclude sales taxes from revenue and expenses. Product sales consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: (a) the Company has transferred physical possession of the products, (b) the Company has a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Based on the shipping terms specified in the sales agreements and purchase orders, these criteria are generally met when the products are shipped from the Company’s facilities (“FOB origin”, which is the Company’s standard shipping terms). As a result, the Company determined that the customer is able to direct the use of, and obtain substantially all of the benefits from, the products at the time the products are shipped. The Company may, may 30 60 Customers may one one one All amounts billed to a customer in a sales transaction related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. Variable Consideration The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do not Warranty The Company generally provides one no not Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of March 31, 2018, December 31, 2017, $241,764 $137,499, three March 31, 2018, not The Company deferred revenues related primarily to maintenance plans of $38,856 $6,663 March 31, 2018 December 31, 2017, Practical Expedients The Company has elected the practical expedient not

Note 3 - Stockholders' Equity,

Note 3 - Stockholders' Equity, Stock Options and Warrants	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 3 2015 On August 31, 2015 ( 1,666,667 $9.00 $8.28 $0.72 8.00% $13.8 45 250,000 not 1% $70,000. On August 31, 2015, 228,343 1,895,010 75,801 1,895,010 7,580,040 Each Unit consisted of one $0.01 one four February 29, 2016. For a description of the terms of the Series B Convertible Preferred Stock included within the Units, see “Series B Preferred Stock” below. For a description of the terms of the Series A Warrants included within the Units, see “Series A Warrants” below. Series A Warrants August 31, 2020. one $123.75 Holders may Total Shares = (A x Where: · Total Shares is the number of shares of Common Stock to be issued upon a Cashless Exercise. · A is the total number of shares with respect to which the Series A Warrant is then being exercised. · B is the Black-Scholes Value. · C is the closing bid price of the Common Stock as of two no may $0.43 The Black-Scholes Value as of September 30, 2016 $4.319, September 30, 2016, $4.125. 40 6,141,115 September 30, 2016, 2,318,663 35,084 August 31, 2015 two $0.43 $4.319 September 30, 2016), 564 The Series A Warrants will not 4.99% 13 1934, In addition to (but not three 1 2 Unit Purchase Option. The Company, in connection with the Offering, entered into a Unit Purchase Option Agreement, dated as of August 31, 2015 ( 5% 83,333 125% $11.25 Series B Preferred Stock. one six not 4.99% no No Unit Exchange. February 4, 2014, $2,055,000 20,550 $0.01, $100 February 4, 2014. August 31, 2015, 228,343 3,991 3 9 August 31, 2015, no Redemption of Convertible Notes. $933,074 40% $1,548,792. 3. $167,031 Registered Exchange Offer for Warrants. March 25, 2016, $0.01 3,157,186 March 31, 2016, 10.05 may one 10.2 one April 21, 2016. 1,770,556 18,059,671 March 31, 2016 July 6, 2016 1,251,510 20,122 2016 On November 29, 2016, $1,983,337. 756,999 $2.62 five 756,999 six $4.46 $1,739,770. 2017 On November 30, 2017, 1,213,819 $1.071 606,910 $1.26 five one six $1,300,000 1.167 1,250,269 142,466 $189,285. 2018 In January 2018, 2,900,000 $0.95 one 0.3 one $1.00 $2,755,000, 45 290,000 87,000 $0.001 February 21, 2018, 215,247 $0.01, $0.9497 $188,066 $16,354 8% Share Exchange Agreement With Helomics On January 11, 2018, 2,500,000 1,100,000 March 2018 $500,000 5% 25% $500,000 1,100,000 12 $8,000,000. 20% may Increases in Authorized Shares At a special meeting of the stockholders on January 29, 2017, 8,000,000 24,000,000 At the annual meeting on December 28, 2017, 24,000,000 50,000,000 $0.01 January 2, 2018. Equity Incentive Plan The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three three ten Accounting for share-based payment The Company uses the Black-Scholes option valuation model which requires the input of significant assumptions including an estimate of the average period of time employees will retain vested stock options before exercising them, the estimated volatility of the Company's common stock price over the expected term, the expected dividend rate, the risk-free interest rate, and forfeiture taken at occurrence. Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognized. The assumptions the Company uses in calculating the fair value of stock-based payment awards represent the Company's best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future. Since the Company's common stock has no no 2 7 15 10 When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized. Since the Company has limited trading history in its stock and no first Valuation and accounting for options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. On January 15, 2018, 50,000 $0.01 $0.97 four third fourth On March 12, 2018, 111,112 $0.01 $1.35 four third fourth For grants of stock option and warrants in 2018 2.33% 2.87% 0% 59% 66% 5 10 $0.4816 $1.0044 The following summarizes transactions for stock options and warrants for the periods indicated: Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2016 165,643 $ 11.22 871,101 $ 52.22 Issued 2,612,070 1.45 1,082,946 1.49 Expired (12,730 ) 10.39 (2,790 ) 281.46 Exercised - - - - Outstanding at December 31, 2017 2,764,983 $ 2.00 1,951,257 $ 23.74 Issued 325,595 1.11 957,000 1.00 Expired - - (9,580 ) 180.12 Exercised - - (38,625 ) 1.00 Outstanding at March 31, 2018 3,090,578 $ 1.89 2,860,052 $ 5.61 At March 31, 2018, 1,957,291 $2.18 9.23 2,860,052 three March 2018 March 2017 $226,387 $99,307, $1,180,348 18 The following summarizes the status of options and warrants outstanding at March 31, 2018: Range of Prices Shares Weighted Remaining Life Options $ 0.97 191,753 9.77 $ 1.01 124,358 9.76 $ 1.10 22,730 10.00 $ 1.35 111,112 9.96 $ 1.454 17,200 9.51 $ 1.47 2,456,226 9.24 $ 2.10 14,286 9.01 $ 2.25 293 8.41 $ 2.42 24,768 8.39 $ 2.80 57,145 8.76 $ 3.75 44,000 8.26 $ 4.125 3,636 8.51 $ 4.1975 7,147 8.47 $ 4.25 3,529 8.01 $ 5.125 3,902 8.44 $ 65.75 190 7.56 $ 73.50 1,157 7.76 $ 77.50 2,323 7.25 $ 80.25 187 7.51 $ 86.25 232 7.01 $ 131.25 81 4.44 $ 148.125 928 4.97 $ 150.00 1,760 4.38 $ 162.50 123 6.76 $ 206.25 121 6.51 $ 248.4375 121 5.29 $ 262.50 130 5.29 $ 281.25 529 4.80 $ 318.75 3 5.11 $ 346.875 72 6.01 $ 431.25 306 5.94 $ 506.25 188 5.76 $ 596.25 42 5.50 3,090,578 Warrants $ 1.00 1,675,374 4.39 $ 1.07 697,946 4.60 $ 2.25 385,000 3.82 $ 123.75 94,084 2.42 $ 243.75 2,529 1.35 $ 309.375 2,850 1.36 $ 309.50 222 1.61 $ 337.50 178 0.22 $ 371.25 946 0.16 $ 506.25 59 0.88 $ 609.375 862 0.85 2,860,052 At the annual meeting on December 28, 2017, 2012 5,000,000, December 4, 2017, 2012 2016 July 28, 2016 not 2.5 2016 not 2012 2017 December 28, 2017. $1.9 fourth 2017. Stock Options and Warrants Granted by the Company The following table is the listing of stock options and warrants as of March 31, 2018 Stock Options: Year Shares Price 2011 173 $281.25 2012 1,841 131.25 – 150.00 2013 1,553 148.125 – 596.25 2014 836 162.50 – 431.25 2015 4,088 65.75 – 86.25 2016 144,422 2.25 – 5.13 2017 2,612,070 1.01 – 2.10 2018 325,595 0.97 – 1.35 Total 3,090,578 $0.97 – 596.25 Warrants: Year Shares Price 2013 1,126 337.50 – 371.25 2014 6,455 243.75 – 609.38 2015 94,151 0.00 – 243.75 2016 756,999 4.46 2017 1,082,946 1.07 – 2.25 2018 918,375 1.00 Total 2,860,052 $0.00 – 609.38

Note 4 - Notes Receivable

Note 4 - Notes Receivable	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Financing Receivables [Text Block]	NOTE 4 In July 2017, 8% December 31, 2017. $1,070,000 December 31, 2017. March 2018, $1,112,524, eight 8% two February 28, 2020. In October 2017, $600,000 8% April 30, 2018. December 2017, $67,512.10 fifty 50% March 2018, $500,000 833,333 5% 25%. $167,512.10

Note 5 - Loss Per Share

Note 5 - Loss Per Share	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 5 The following table presents the shares used in the basic and diluted loss per common share computations: Three Months Ended March 31, 2018 2017 Numerator: Net loss available in basic and diluted calculation $ (1,760,022 ) $ (1,341,847 ) Other comprehensive income: Unrealized gain from marketable securities - - Comprehensive (loss) (1,760,022 ) (1,341,847 ) Denominator: Weighted average common shares outstanding-basic 11,383,217 6,450,967 Effect of diluted stock options, warrants and preferred stock (1) - - Weighted average common shares outstanding-basic 11,383,217 6,450,967 Loss per common share-basic and diluted $ (0.15 ) $ (0.21 ) ( 1 March 31, 2018 March 31, 2017 5,950,630 1,427,558 March 31, 2018 79,246.

Note 6 - Income Taxes

Note 6 - Income Taxes	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 6 The provision for income taxes consists of an amount for taxes currently payable and a provision for tax consequences deferred to future periods. Deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Tax Reform Act was enacted December 22, 2017. January 1, 2018, 34% 21%. no 100% There is no 100% During September 2013, 382 may September 2013, not At December 31, 2017, $34.5 2018, 382 2022 $12.2 December 31, 2017. 2017 December 31, 2017, $7.4 $0.2 At March 31, 2018, $36.1 2018, 382 2022 $12.4 March 31, 2018. 2017 March 31, 2018, $7.7 $1.0 The valuation allowance has been recorded due to the uncertainty of realization of the benefits associated with the net operating losses. Future events and changes in circumstances could cause this valuation allowance to change. The components of deferred income taxes at March 31, 2018 December 31, 2017 March 31, 2018 December 31, Deferred Tax Asset: Net Operating Loss $ 8,554,404 $ 7,393,000 Other 192,522 215,843 Total Deferred Tax Asset 8,746,926 7,608,943 Less Valuation Allowance 8,746,926 7,608,943 Net Deferred Income Taxes $ — $ —

Note 7 - Rent Obligation

Note 7 - Rent Obligation	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Leases of Lessee Disclosure [Text Block]	NOTE 7 On November 22, 2017, second January 28, 2013. three February 1, 2018 January 31, 2021. 5,773 2,945 2,828 January 31, 2021. $17,244 $16,895 three March 31, 2018 March 31, 2017, The Company’s rent obligation for the next four 2018 $ 29,250 2019 $ 40,000 2020 $ 42,000 2021 $ 3,000

Note 8 - Related Party Transact

Note 8 - Related Party Transactions	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 8 The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may In April 2018, one six $12,000 240,000 2012 Richard L. Gabriel, is the Chief Operating Officer and serves as a director of GLG Pharma (“GLG”). Another Company director, Tim Krochuk, is on the supervisory board for GLG. In September 20, 2016, 400,000 four 100,000 November 1, 2016, November 2, 2016, April 2017,

Note 9 - Retirement Savings Pla

Note 9 - Retirement Savings Plan	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	NOTE 9 The Company has a pre-tax salary reduction/profit-sharing plan under the provisions of Section 401 2018 2017, 100% 4% $11,907 $9,770 three March 31, 2018 March 31, 2017,

Note 10 - Subsequent Events

Note 10 - Subsequent Events	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 10 In April 2018, one six $12,000 240,000 2012 On April 20, 2018, On the effective date of the proposed Merger, Precision would issue to Helomics’ stockholders 7.5 1.1 20% January 2018 The letter of intent is non-binding except for certain enumerated provisions. Completion of the Merger is subject to confirmatory due diligence and negotiation and execution of a definitive merger agreement. There will be certain conditions to closing, including approval of the Merger by the boards of directors and stockholders of Precision and Helomics, the receipt of all necessary approvals and consents of governmental bodies, lenders, lessors and third no no

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Nature of Operations and Continuance of Operations Precision Therapeutics Inc., (the “Company”) was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. As of March 31, 2018, 11,804,073 $.01 In April 2009, 510 25% first The accompanying condensed consolidated financial statements (the “financial statements”) have been prepared assuming the Company will continue as a going concern. The Company has incurred recurring losses from operations and has an accumulated deficit of $56,525,066. $2,232,803 March 31, 2018 not Since inception to March 31, 2018, $35,840,380 1 $2,055,000 2 $13,555,003 3 $1,739,770 4 $3,937,500 $358,312 5 $1,300,000 6 $2,755,000 7 $5,685,000
Interim Financial Statements, Policy [Policy Text Block]	Interim Financial Statements The Company has prepared the unaudited interim financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which in the opinion of management, are necessary to present fairly the Company’s position, the results of its operations and its cash flows for the interim periods. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Form 10 April 2, 2018. may not
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Developments In May 2014, No. 2014 09, 606 January 1, 2018 not December 31, 2017. January 1, 2018 606, not 605, Revenue Recognition not December 31, 2017, not January 1, 2018. 2 In January 2016, No. 2016 01, Financial Instruments-Overall (Subtopic 825 10 2016 01” not not December 15, 2017, March 31, 2018, no In February 2016, No. 2016 02, Leases (Topic 842 2016 02” December 15, 2018. On December 22, 2017, 2017 34% 21%. The Company reviewed all other significant newly issued accounting pronouncements and determined they are either not no
Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]	Valuation of Intangible Assets The Company reviews identifiable intangible assets for impairment annually, or whenever events or changes in circumstances indicate the carrying amount may not may not not
Use of Estimates, Policy [Policy Text Block]	Accounting Policies and Estimates The presentation of financial statements is in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Advertising Costs, Policy [Policy Text Block]	Advertising Advertising costs are expensed as incurred. Advertising expenses were $4,394 three March 31, 2018 $4,271 three March 31, 2017.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are charged to operations as incurred. Research and development expenses were $94,011 three March 31, 2018 $84,472 three March 31, 2017.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Equivalents The Company considers all highly liquid debt instruments with a maturity of three
Certificates of Deposit Policy [Policy Text Block]	Certificates of Deposit Short-term interest-bearing investments are those with maturities of less than one three one
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements Under generally accepted accounting principles as outlined in the FASB’s Accounting Standards Codification 820, 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities was determined based on Level 1
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost and net realizable value, with cost determined on a first first March 31, 2018 December 31, 2017 Finished goods $ 32,967 $ 62,932 Raw materials 183,216 141,028 Work-In-Process 56,373 61,085 Total $ 272,556 $ 265,045
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing tooling 3 - 7 Demo equipment 3 The Company’s investment in fixed assets consists of the following: March 31, December 31, Computers and office equipment $ 190,484 $ 183,528 Leasehold improvements 41,397 25,635 Manufacturing tooling 108,955 108,955 Demo equipment 53,439 43,368 Total 394,275 361,486 Less: Accumulated depreciation 288,266 273,770 Total Fixed Assets, Net $ 106,009 $ 87,716 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Depreciation expense was $14,496 three March 31, 2018, $15,685 three March 31, 2017.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible Assets Intangible assets consist of trademarks and patent costs. Amortization expense was $3,671 three March 31, 2018, $2,888 three March 31, 2017.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes 740” 740, There is no 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no Tax years subsequent to 2014
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patents and Intellectual Property On January 25, 2014, No. PCT/US2014/013081 61756763 one January 25, 2013. 148 The Company’s PCT patent application is for the new model of the surgical fluid waste management system. The Company obtained a favorable International Search Report from the PCT searching authority indicating that the claims in its PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facility’s sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 No. US20090216205 August 8, 2023. In July 2015, The United States Patent Office has assigned application #14/763,459 As of November 22, 2017, #14743665.3 1651,
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one $1,984,163
Segment Reporting, Policy [Policy Text Block]	Segments The Company operates in two three March 31, 2018 2017 $26,662 2017 first March 2017.
Risks and Uncertainties Policy [Policy Text Block]	Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not

Note 1 - Summary of Significa19

Note 1 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, 2018 December 31, 2017 Finished goods $ 32,967 $ 62,932 Raw materials 183,216 141,028 Work-In-Process 56,373 61,085 Total $ 272,556 $ 265,045
Property Plant and Equipment UsefulLife [Table Text Block]	Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing tooling 3 - 7 Demo equipment 3
Property, Plant and Equipment [Table Text Block]	March 31, December 31, Computers and office equipment $ 190,484 $ 183,528 Leasehold improvements 41,397 25,635 Manufacturing tooling 108,955 108,955 Demo equipment 53,439 43,368 Total 394,275 361,486 Less: Accumulated depreciation 288,266 273,770 Total Fixed Assets, Net $ 106,009 $ 87,716

Note 3 - Stockholders' Equity20

Note 3 - Stockholders' Equity, Stock Options and Warrants (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Share-based Compensation, Activity [Table Text Block]	Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2016 165,643 $ 11.22 871,101 $ 52.22 Issued 2,612,070 1.45 1,082,946 1.49 Expired (12,730 ) 10.39 (2,790 ) 281.46 Exercised - - - - Outstanding at December 31, 2017 2,764,983 $ 2.00 1,951,257 $ 23.74 Issued 325,595 1.11 957,000 1.00 Expired - - (9,580 ) 180.12 Exercised - - (38,625 ) 1.00 Outstanding at March 31, 2018 3,090,578 $ 1.89 2,860,052 $ 5.61
Schedule of Share-based Compensation Shares Authorized Under Stock Option and Warrant Plans by Exercise Price Range [Table Text Block]	Range of Prices Shares Weighted Remaining Life Options $ 0.97 191,753 9.77 $ 1.01 124,358 9.76 $ 1.10 22,730 10.00 $ 1.35 111,112 9.96 $ 1.454 17,200 9.51 $ 1.47 2,456,226 9.24 $ 2.10 14,286 9.01 $ 2.25 293 8.41 $ 2.42 24,768 8.39 $ 2.80 57,145 8.76 $ 3.75 44,000 8.26 $ 4.125 3,636 8.51 $ 4.1975 7,147 8.47 $ 4.25 3,529 8.01 $ 5.125 3,902 8.44 $ 65.75 190 7.56 $ 73.50 1,157 7.76 $ 77.50 2,323 7.25 $ 80.25 187 7.51 $ 86.25 232 7.01 $ 131.25 81 4.44 $ 148.125 928 4.97 $ 150.00 1,760 4.38 $ 162.50 123 6.76 $ 206.25 121 6.51 $ 248.4375 121 5.29 $ 262.50 130 5.29 $ 281.25 529 4.80 $ 318.75 3 5.11 $ 346.875 72 6.01 $ 431.25 306 5.94 $ 506.25 188 5.76 $ 596.25 42 5.50 3,090,578 Warrants $ 1.00 1,675,374 4.39 $ 1.07 697,946 4.60 $ 2.25 385,000 3.82 $ 123.75 94,084 2.42 $ 243.75 2,529 1.35 $ 309.375 2,850 1.36 $ 309.50 222 1.61 $ 337.50 178 0.22 $ 371.25 946 0.16 $ 506.25 59 0.88 $ 609.375 862 0.85 2,860,052
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Stock Options: Year Shares Price 2011 173 $281.25 2012 1,841 131.25 – 150.00 2013 1,553 148.125 – 596.25 2014 836 162.50 – 431.25 2015 4,088 65.75 – 86.25 2016 144,422 2.25 – 5.13 2017 2,612,070 1.01 – 2.10 2018 325,595 0.97 – 1.35 Total 3,090,578 $0.97 – 596.25 Warrants: Year Shares Price 2013 1,126 337.50 – 371.25 2014 6,455 243.75 – 609.38 2015 94,151 0.00 – 243.75 2016 756,999 4.46 2017 1,082,946 1.07 – 2.25 2018 918,375 1.00 Total 2,860,052 $0.00 – 609.38

Note 5 - Loss Per Share (Tables

Note 5 - Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended March 31, 2018 2017 Numerator: Net loss available in basic and diluted calculation $ (1,760,022 ) $ (1,341,847 ) Other comprehensive income: Unrealized gain from marketable securities - - Comprehensive (loss) (1,760,022 ) (1,341,847 ) Denominator: Weighted average common shares outstanding-basic 11,383,217 6,450,967 Effect of diluted stock options, warrants and preferred stock (1) - - Weighted average common shares outstanding-basic 11,383,217 6,450,967 Loss per common share-basic and diluted $ (0.15 ) $ (0.21 )

Note 6 - Income Taxes (Tables)

Note 6 - Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	March 31, 2018 December 31, Deferred Tax Asset: Net Operating Loss $ 8,554,404 $ 7,393,000 Other 192,522 215,843 Total Deferred Tax Asset 8,746,926 7,608,943 Less Valuation Allowance 8,746,926 7,608,943 Net Deferred Income Taxes $ — $ —

Note 7 - Rent Obligation (Table

Note 7 - Rent Obligation (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Rent Expense [Table Text Block]	2018 $ 29,250 2019 $ 40,000 2020 $ 42,000 2021 $ 3,000

Note 1 - Summary of Significa24

Note 1 - Summary of Significant Accounting Policies (Details Textual)	Nov. 29, 2016USD ($)	Aug. 31, 2015USD ($)	Jan. 31, 2018USD ($)	Mar. 31, 2018USD ($)$ / sharesshares	Mar. 31, 2017USD ($)	Dec. 31, 2018	Dec. 31, 2017USD ($)$ / sharesshares	Mar. 31, 2018USD ($)$ / sharesshares	Feb. 21, 2018$ / shares	Dec. 28, 2017$ / shares	Dec. 31, 2016USD ($)
Common Stock, Shares, Outstanding, Ending Balance | shares				11,804,073			6,943,283	11,804,073
Common Stock, Par or Stated Value Per Share | $ / shares				$ 0.01			$ 0.01	$ 0.01	$ 0.01	$ 0.01
Retained Earnings (Accumulated Deficit), Ending Balance				$ (56,525,066)			$ (54,765,045)	$ (56,525,066)
Cash and Cash Equivalents, at Carrying Value, Ending Balance				2,232,803	$ 2,086,408		766,189	2,232,803			$ 1,764,090
Stockholders' Equity, Period Increase (Decrease), Total								35,840,380
Stock Issued During Period, Value, New Issues				2,755,087			$ 3,421,188
Proceeds from Issuance or Sale of Equity, Total		$ 13,800,000
Debt Instrument, Increase (Decrease), Net, Total								$ 5,685,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent							34.00%
Advertising Expense				4,394	4,271
Research and Development Expense, Total				94,011	84,472
Depreciation, Total				14,496	15,685
Amortization of Intangible Assets, Total				$ 3,671	$ 2,888
Valuation Allowance Percentage				100.00%				100.00%
Cash, Uninsured Amount				$ 1,984,163				$ 1,984,163
Number of Operating Segments				2
Non-US [Member]
Revenues, Total							$ 26,662
Earliest Tax Year [Member]
Open Tax Year				2,014
Scenario, Forecast [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent						21.00%
Private Placement [Member]
Stock Issued During Period, Value, New Issues							1,213,819
IPO [Member]
Stock Issued During Period, Value, New Issues								13,555,003
Proceeds from Issuance or Sale of Equity, Total								3,937,500
The 2016 Registered Direct Offering [Member]
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs	$ 1,739,770							1,739,770
Proceeds from Issuance or Sale of Equity, Total	$ 1,983,337
Over-Allotment Option [Member]
Stock Issued During Period, Value, New Issues				$ 204,422			$ 393,750
Proceeds from Issuance or Sale of Equity, Total								358,312
The 2018 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total			$ 2,755,000					2,755,000
Series A Convertible Preferred Stock [Member] | Private Placement [Member]
Stock Issued During Period, Value, New Issues								2,055,000
Series C Convertible Preferred Stock [Member] | Private Placement [Member]
Stock Issued During Period, Value, New Issues								$ 1,300,000
Helomics Holding Corp. [Member]
Share Exchange Agreement, Potential Interest				25.00%				25.00%

Note 1 - Summary of Significa25

Note 1 - Summary of Significant Accounting Policies - Schedule of Inventory (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Finished goods	$ 32,967	$ 62,932
Raw materials	183,216	141,028
Work-In-Process	56,373	61,085
Total	$ 272,556	$ 265,045

Note 1 - Summary of Significa26

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details)	3 Months Ended
	Mar. 31, 2018
Leasehold Improvements [Member]
Property, plant, and equipment, useful life (Year)	5 years
Demo Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	3 years
Maximum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	7 years
Maximum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	7 years

Note 1 - Summary of Significa27

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Property, Plant, and Equipment Gross	$ 394,275	$ 361,486
Less: Accumulated depreciation	288,266	273,770
Total Fixed Assets, Net	106,009	87,716
Office Equipment [Member]
Property, Plant, and Equipment Gross	190,484	183,528
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	41,397	25,635
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	108,955	108,955
Demo Equipment [Member]
Property, Plant, and Equipment Gross	$ 53,439	$ 43,368

Note 2 - Revenue Recognition (D

Note 2 - Revenue Recognition (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Maintenance Plan, Service Requirement, Period Subsequent to One Year Anniversary of Invoice	1 year
Standard Product Warranty, Term	1 year
Accounts Receivable, Net, Current, Total	$ 241,764	$ 137,499
Contract with Customer, Liability, Current	$ 38,856	$ 6,663
Minimum [Member]
Standard Payment Term for Customers	30 days
Maximum [Member]
Standard Payment Term for Customers	60 days

Note 3 - Stockholders' Equity29

Note 3 - Stockholders' Equity, Stock Options and Warrants (Details Textual)	Apr. 01, 2018USD ($)shares	Mar. 12, 2018$ / sharesshares	Feb. 21, 2018USD ($)$ / sharesshares	Jan. 15, 2018$ / sharesshares	Jan. 11, 2018USD ($)shares	Nov. 30, 2017USD ($)$ / sharesshares	Nov. 29, 2016USD ($)$ / sharesshares	Mar. 31, 2016shares	Aug. 31, 2015USD ($)$ / sharesshares	Feb. 04, 2014USD ($)$ / sharesshares	Jan. 31, 2018USD ($)$ / sharesshares	Mar. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Mar. 31, 2017USD ($)	Jul. 06, 2016shares	Sep. 30, 2016$ / sharesshares	Dec. 31, 2018$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Mar. 31, 2018USD ($)$ / sharesshares	Jan. 02, 2018shares	Dec. 28, 2017$ / sharesshares	Jan. 29, 2017shares	Oct. 27, 2016shares	Apr. 21, 2016shares	Mar. 25, 2016$ / sharesshares
Shares Issued, Price Per Share | $ / shares									$ 9
Underwriter Price | $ / shares									8.28
Underwriting Discount | $ / shares									$ 0.72
Underwriting Commission									8.00%
Proceeds from Issuance or Sale of Equity, Total | $									$ 13,800,000
Option Granted to Underwriter to Purchase Additional Units Period									45 days
Option Granted to Underwriter to Purchase Additional Units Number of Units Granted									250,000
Underwriting Agreement Non-accountable Expense Allowance Percentage									1.00%
Common Stock, Par or Stated Value Per Share | $ / shares			$ 0.01									$ 0.01	$ 0.01					$ 0.01	$ 0.01		$ 0.01
Share Price | $ / shares																$ 4.125
Class of Warrant or Right, Outstanding												2,860,052							2,860,052
Stock Issued During Period, Value, New Issues | $												$ 2,755,087						$ 3,421,188
Common Stock, Shares Authorized												50,000,000	50,000,000					50,000,000	50,000,000		50,000,000	24,000,000	8,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate												0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number												1,957,291							1,957,291
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares												$ 2.18							$ 2.18
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term												9 years 83 days
Class of Warrant or Right Number of Warrants Vested and Exercisable												2,860,052							2,860,052
Allocated Share-based Compensation Expense, Total | $												$ 226,387		$ 99,307
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | $												$ 1,180,348							$ 1,180,348
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost | $													$ 1,900,000
Vice President of Sales [Member]
Common Stock, Par or Stated Value Per Share | $ / shares				$ 0.01
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				50,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares				$ 0.97
Number of Equal Installments Options are Expected to Vest				4
Vice President of Sales and Marketing [Member]
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.01
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		111,112
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares		$ 1.35
Number of Equal Installments Options are Expected to Vest		4
Stock Incentive Plan 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																		2,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																				5,000,000
The 2016 Registered Direct Offering [Member]
Proceeds from Issuance or Sale of Equity, Total | $							$ 1,983,337
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares							$ 4.46
Share Price | $ / shares							$ 2.62
Stock Issued During Period, Shares, New Issues							756,999
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							756,999
Class of Warrant or Right Term							5 years
Class of Warrant or Right, Vesting Period							180 days
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs | $							$ 1,739,770												1,739,770
Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares						$ 1.26
Stock Issued During Period, Value, New Issues | $																		$ 1,213,819
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						606,910
Class of Warrant or Right Term						5 years 182 days
Class of Warrant or Right, Vesting Period						180 days
Proceeds from Issuance of Convertible Preferred Stock | $						$ 1,300,000
The 2018 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total | $											$ 2,755,000								$ 2,755,000
Share Price | $ / shares											$ 0.95
Stock Issued During Period, Shares, New Issues											2,900,000
Over-Allotment Option [Member]
Shares Issued, Price Per Share | $ / shares			$ 0.9497									$ 0.9497							$ 0.9497
Proceeds from Issuance or Sale of Equity, Total | $																			$ 358,312
Stock Issued During Period, Value, New Issues | $												$ 204,422						$ 393,750
Stock Issued During Period, Shares, New Issues			215,247
Sale of Stock, Underwriter Option Term											45 days
Sale of Stock, Underwriter Option, Maximum Additional Shares of Common Stock Available for Purchase											290,000
Sale of Stock, Underwriter Option, Number of Securities Called by Maximum Additional Warrants Available for Purchase											87,000
Sale of Stock, Underwriter Option, Exercise Price of Additional Warrants Available for Purchase | $ / shares											$ 0.001
Proceeds from Underwriter Shares Exercised, Net | $			$ 188,066
Stock Issued During Period, Underwriter Discount | $			$ 16,354
Underwriter Discount Percentage			8.00%
Conversion from Series C Convertible Preferred Stock to Common Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion												1.167							1.167
Conversion of Stock, Shares Issued												1,250,269
The Convertible Notes [Member]
Debt Instrument Redemption Principal Amount | $									$ 933,074
Debt Instrument Redemption Premium Percentage									40.00%
Debt Instrument Redemption Price | $									$ 1,548,792
Debt Instrument Redemption Amount Paid to Affiliates | $									$ 167,031
Series B Convertible Preferred Stock [Member]
Beneficial Ownership Limitation Percentage												4.99%
Stock Issued During Period, Value, New Issues | $										$ 2,055,000
Stock Issued During Period, Shares, New Issues										20,550
Preferred Stock Par Value | $ / shares										$ 0.01
Preferred Stock Stated Value | $ / shares										$ 100
Preferred Stock, Shares Outstanding, Ending Balance												79,246	79,246					79,246	79,246
Series A Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance									0
Series C Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance												0	647,819					647,819	0
Series A Warrants [Member] | Exchange Offer [Member]
Stock to be Issued for Exchange Offer, Shares, Maximum																									3,157,186
Cashless Exercise of Common Stock Warrants, Total								10.05
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																								1,770,556
Exchange from Series B Warrants to Warrant Shares [Member] | Exchange Offer [Member]
Common Stock, Par or Stated Value Per Share | $ / shares																									$ 0.01
Series B Warrants [Member] | Exchange Offer [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right								1
Class of Warrant or Right Exercised During Period															1,251,510
Stock Issued During Period, Shares, Warrants Exercised															20,122
Cashless Exercise of Common Stock Warrants, Total								10.2
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																								18,059,671
Series E Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares												$ 1							$ 1
Series E Warrants [Member] | The 2018 Public Offering [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right											1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares											$ 1
Class of Warrant or Right, Issued per Unit											0.3
Common Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities												589,747						660,522
Stock Issued During Period, Value, New Issues | $												$ 29,000						$ 17,500
Stock Issued During Period, Shares, New Issues												2,900,000						1,750,000
Common Stock [Member] | Private Placement [Member]
Stock Issued During Period, Value, New Issues | $
Stock Issued During Period, Shares, New Issues
Common Stock [Member] | Over-Allotment Option [Member]
Stock Issued During Period, Value, New Issues | $												$ 2,153						$ 1,750
Stock Issued During Period, Shares, New Issues												215,247						175,000
Common Stock [Member] | Series E Warrants [Member]
Stock Issued During Period, Shares, Warrants Exercised												55,796
Preferred Stock [Member]
Stock Issued During Period, Value, New Issues | $
Preferred Stock [Member] | Private Placement [Member]
Stock Issued During Period, Value, New Issues | $																		12,138
Preferred Stock [Member] | Over-Allotment Option [Member]
Stock Issued During Period, Value, New Issues | $
Preferred Stock [Member] | Series C Convertible Preferred Stock [Member] | Subsequent Event [Member]
Stock Redeemed or Called During Period, Shares	142,466
Payments for Repurchase of Convertible Preferred Stock | $	$ 189,285
Preferred Stock [Member] | Series C Convertible Preferred Stock [Member] | Private Placement [Member]
Shares Issued, Price Per Share | $ / shares						$ 1.071
Stock Issued During Period, Shares, New Issues						1,213,819
Corporate Stock Transfer Inc. [Member]
Unit Agreement Number of Shares of Common Stock Included in Each Unit									1
Common Stock, Par or Stated Value Per Share | $ / shares									$ 0.01
Corporate Stock Transfer Inc. [Member] | Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right																40
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares												$ 123.75							123.75
Cash Less Exercise Formula Definition of Letter C in the Formula Closing Bid Price Number of Trading Days Prior to the Time of Exercise												2 days
Cash Less Exercise Formula Closing Bid Price Per Share Minimum to Be Used in the Formula | $ / shares												$ 0.43							$ 0.43
Warrants Option to Settle in Cash Fair Value Disclosure | $ / shares																$ 4.319
Class of Warrant or Right Exercised During Period																6,141,115
Stock Issued During Period, Shares, Warrants Exercised																2,318,663
Class of Warrant or Right, Outstanding												35,084							35,084
Class of Warrant or Right Cash less Exercise Common Stock Price That Would Result in a Dilutive Exercise | $ / shares												$ 0.43							$ 0.43
Beneficial Ownership Limitation Percentage												4.99%
Corporate Stock Transfer Inc. [Member] | Series A Warrants [Member] | Scenario, All Outstanding Warrants Exercised at Minimum Bid Price [Member]
Stock Issued During Period, Shares, Warrants Exercised																564
Corporate Stock Transfer Inc. [Member] | Series B Convertible Preferred Stock [Member]
Unit Agreement Number of Shares of Common Stock Included in Each Unit									1
Corporate Stock Transfer Inc. [Member] | Series A Convertible Preferred Stock [Member]
Unit Agreement Number of Shares of Common Stock Included in Each Unit									4
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right									1
Helomics Holding Corp. [Member]
Stock Issued During Period, Shares, New Issues					1,100,000
Share Exchange Agreement, Shares Received					2,500,000
Share Exchange Agreement, Convertible Notes Receivable | $												$ 500,000							$ 500,000
Share Exchange Agreement, Convertible Notes, Percent of Stock												5.00%							5.00%
Share Exchange Agreement, Potential Interest												25.00%							25.00%
Share Exchange Agreement, Number of Shares Held in Escrow												1,100,000							1,100,000
Share Exchange Agreement, Contingent Revenue, Minimum | $					$ 8,000,000
Convertible Preferred Stock Held, Conversion Feature, Percent					20.00%
Maximum [Member]
Underwriting Agreement Expenses Agreed to Reimburse the Underwriter | $									$ 70,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares												$ 609.38							$ 609.38
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares												$ 596.25
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate												2.87%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate												66.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term												10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares												$ 1.0044
Maximum [Member] | Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period												3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period												10 years
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares												$ 0							$ 0
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares												$ 0.97
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate												2.33%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate												59.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term												5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares												$ 0.4816
Minimum [Member] | Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period												3 years
Exchange Units [Member]
Unit Purchase Option Units Sold									1,666,667
Stock Issued During Period, Shares, Conversion of Convertible Securities									1,895,010
Exchange Units [Member] | Series A Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities									3,991
Exchange Units [Member] | Series A Warrants [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities									7,580,040
Exchange Units [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities									75,801
Exchange Units [Member] | Series B Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities									1,895,010
Exchange Units [Member] | Corporate Stock Transfer Inc. [Member]
Unit Purchase Option Units Issued									228,343
Unit Purchase Option Number of Units Available for Underwriter to Purchase, Percentage									5.00%
Unit Purchase Option Number of Units Available For Underwriter to Purchase									83,333
Unit Purchase Option Exercise Price, Percentage									125.00%
Unit Purchase Option Exercise Price | $ / shares									$ 11.25
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																	325,595	2,612,070
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares																	$ 1.11	$ 1.45
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition												1 year 180 days

Note 3 - Stockholders' Equity30

Note 3 - Stockholders' Equity, Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Number of Shares Outstanding (in shares)	3,090,578
Warrant [Member]
Number of Shares Outstanding (in shares)	1,951,257	1,951,257	871,101
Average Exercise Price Outstanding (in dollars per share)	$ 23.74	$ 23.74	$ 52.22
Number of Shares Issued (in shares)		957,000	1,082,946
Average Exercise Price Issued (in dollars per share)		$ 1	$ 1.49
Number of Shares Expired (in shares)		(9,580)	(2,790)
Average Exercise Price Expired (in dollars per share)		$ 180.12	$ 281.46
Number of Shares Exercised (in shares)		(38,625)
Average Exercise Price Exercised (in dollars per share)		$ 1
Number of Shares Outstanding (in shares)		2,860,052	1,951,257
Average Exercise Price Outstanding (in dollars per share)		$ 5.61	$ 23.74
Employee Stock Option [Member]
Number of Shares Outstanding (in shares)	2,764,983	2,764,983	165,643
Average Exercise Price Outstanding (in dollars per share)	$ 2	$ 2	$ 11.22
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		325,595	2,612,070
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 1.11	$ 1.45
Number of Shares Expired (in shares)			(12,730)
Average Exercise Price Expired (in dollars per share)			$ 10.39
Number of Shares Exercised (in shares)
Average Exercise Price Exercised (in dollars per share)
Number of Shares Outstanding (in shares)		3,090,578	2,764,983
Average Exercise Price Outstanding (in dollars per share)		$ 1.89	$ 2

Note 3 - Stockholders' Equity31

Note 3 - Stockholders' Equity, Stock Options and Warrants - Summary of Status of Options and Warrants Outstanding (Details)	3 Months Ended
	Mar. 31, 2018$ / sharesshares
Shares, options (in shares)	3,090,578
Shares, warrants (in shares)	2,860,052
Weighted average remaining life, warrants (Year)
Warrant One [Member]
Exercise price per share (in dollars per share) | $ / shares	$ 1
Shares, warrants (in shares)	1,675,374
Weighted average remaining life, warrants (Year)	4 years 142 days
Warrant Two [Member]
Exercise price per share (in dollars per share) | $ / shares	$ 1.07
Shares, warrants (in shares)	697,946
Weighted average remaining life, warrants (Year)	4 years 219 days
Warrant Three [Member]
Exercise price per share (in dollars per share) | $ / shares	$ 2.25
Shares, warrants (in shares)	385,000
Weighted average remaining life, warrants (Year)	3 years 299 days
Warrant Four [Member]
Exercise price per share (in dollars per share) | $ / shares	$ 123.75
Shares, warrants (in shares)	94,084
Weighted average remaining life, warrants (Year)	2 years 153 days
Warrant Five [Member]
Exercise price per share (in dollars per share) | $ / shares	$ 243.75
Shares, warrants (in shares)	2,529
Weighted average remaining life, warrants (Year)	1 year 127 days
Warrant Six [Member]
Exercise price per share (in dollars per share) | $ / shares	$ 309.375
Shares, warrants (in shares)	2,850
Weighted average remaining life, warrants (Year)	1 year 131 days
Warrant Seven [Member]
Exercise price per share (in dollars per share) | $ / shares	$ 309.50
Shares, warrants (in shares)	222
Weighted average remaining life, warrants (Year)	1 year 222 days
Warrant Eight [Member]
Exercise price per share (in dollars per share) | $ / shares	$ 337.50
Shares, warrants (in shares)	178
Weighted average remaining life, warrants (Year)	80 days
Warrant Nine [Member]
Exercise price per share (in dollars per share) | $ / shares	$ 371.25
Shares, warrants (in shares)	946
Weighted average remaining life, warrants (Year)	58 days
Warrant Ten [Member]
Exercise price per share (in dollars per share) | $ / shares	$ 506.25
Shares, warrants (in shares)	59
Weighted average remaining life, warrants (Year)	321 days
Warrant Eleven [Member]
Exercise price per share (in dollars per share) | $ / shares	$ 609.375
Shares, warrants (in shares)	862
Weighted average remaining life, warrants (Year)	310 days
Stock Options One [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 0.97
Shares, options (in shares)	191,753
Weighted average remaining life, options (Year)	9 years 281 days
Stock Options Two [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 1.01
Shares, options (in shares)	124,358
Weighted average remaining life, options (Year)	9 years 277 days
Stock Options Three [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 1.10
Shares, options (in shares)	22,730
Weighted average remaining life, options (Year)	10 years
Stock Options Four [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 1.35
Shares, options (in shares)	111,112
Weighted average remaining life, options (Year)	9 years 350 days
Stock Options Five [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 1.454
Shares, options (in shares)	17,200
Weighted average remaining life, options (Year)	9 years 186 days
Stock Options Six [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 1.47
Shares, options (in shares)	2,456,226
Weighted average remaining life, options (Year)	9 years 87 days
Stock Options Seven [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 2.10
Shares, options (in shares)	14,286
Weighted average remaining life, options (Year)	9 years 3 days
Stock Options Eight [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 2.25
Shares, options (in shares)	293
Weighted average remaining life, options (Year)	8 years 149 days
Stock Options Nine [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 2.42
Shares, options (in shares)	24,768
Weighted average remaining life, options (Year)	8 years 142 days
Stock Options Ten [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 2.80
Shares, options (in shares)	57,145
Weighted average remaining life, options (Year)	8 years 277 days
Stock Options Eleven [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 3.75
Shares, options (in shares)	44,000
Weighted average remaining life, options (Year)	8 years 94 days
Stock Options Twelve [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 4.125
Shares, options (in shares)	3,636
Weighted average remaining life, options (Year)	8 years 186 days
Stock Options Thirteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 4.1975
Shares, options (in shares)	7,147
Weighted average remaining life, options (Year)	8 years 171 days
Stock Options Fourteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 4.25
Shares, options (in shares)	3,529
Weighted average remaining life, options (Year)	8 years 3 days
Stock Options Fifteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 5.125
Shares, options (in shares)	3,902
Weighted average remaining life, options (Year)	8 years 160 days
Stock Options Sixteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 65.75
Shares, options (in shares)	190
Weighted average remaining life, options (Year)	7 years 204 days
Stock Options Seventeen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 73.50
Shares, options (in shares)	1,157
Weighted average remaining life, options (Year)	7 years 277 days
Stock Options Eighteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 77.50
Shares, options (in shares)	2,323
Weighted average remaining life, options (Year)	7 years 91 days
Stock Options Nineteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 80.25
Shares, options (in shares)	187
Weighted average remaining life, options (Year)	7 years 186 days
Stock Options Twenty [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 86.25
Shares, options (in shares)	232
Weighted average remaining life, options (Year)	7 years 3 days
Stock Options Twenty One [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 131.25
Shares, options (in shares)	81
Weighted average remaining life, options (Year)	4 years 160 days
Stock Options Twenty Two [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 148.125
Shares, options (in shares)	928
Weighted average remaining life, options (Year)	4 years 354 days
Stock Options Twenty Three [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 150
Shares, options (in shares)	1,760
Weighted average remaining life, options (Year)	4 years 138 days
Stock Options Twenty Four [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 162.50
Shares, options (in shares)	123
Weighted average remaining life, options (Year)	6 years 277 days
Stock Options Twenty Five [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 206.25
Shares, options (in shares)	121
Weighted average remaining life, options (Year)	6 years 186 days
Stock Options Twenty Six [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 248.4375
Shares, options (in shares)	121
Weighted average remaining life, options (Year)	5 years 105 days
Stock Options Twenty Seven [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 262.50
Shares, options (in shares)	130
Weighted average remaining life, options (Year)	5 years 105 days
Stock Options Twenty Eight [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 281.25
Shares, options (in shares)	529
Weighted average remaining life, options (Year)	4 years 292 days
Stock Options Twenty Nine [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 318.75
Shares, options (in shares)	3
Weighted average remaining life, options (Year)	5 years 40 days
Stock Options Thirty [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 346.875
Shares, options (in shares)	72
Weighted average remaining life, options (Year)	6 years 3 days
Stock Options Thirty-One [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 431.25
Shares, options (in shares)	306
Weighted average remaining life, options (Year)	5 years 343 days
Stock Options Thirty-Two [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 506.25
Shares, options (in shares)	188
Weighted average remaining life, options (Year)	5 years 277 days
Stock Options Thirty-Three [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 596.25
Shares, options (in shares)	42
Weighted average remaining life, options (Year)	5 years 182 days

Note 3 - Stockholders' Equity32

Note 3 - Stockholders' Equity, Stock Options and Warrants - Schedule of Listing of Stock Options and Warrants (Details)	3 Months Ended
	Mar. 31, 2018$ / sharesshares
Shares, options (in shares) | shares	3,090,578
Shares, warrants (in shares) | shares	2,860,052
Minimum [Member]
Price, options (in dollars per share)	$ 0.97
Exercise price per share (in dollars per share)	0
Maximum [Member]
Price, options (in dollars per share)	596.25
Exercise price per share (in dollars per share)	$ 609.38
Warrants 2013 [Member]
Shares, warrants (in shares) | shares	1,126
Warrants 2013 [Member] | Minimum [Member]
Exercise price per share (in dollars per share)	$ 337.50
Warrants 2013 [Member] | Maximum [Member]
Exercise price per share (in dollars per share)	$ 371.25
Warrants 2014 [Member]
Shares, warrants (in shares) | shares	6,455
Warrants 2014 [Member] | Minimum [Member]
Exercise price per share (in dollars per share)	$ 243.75
Warrants 2014 [Member] | Maximum [Member]
Exercise price per share (in dollars per share)	$ 609.38
Warrants 2015 [Member]
Shares, warrants (in shares) | shares	94,151
Warrants 2015 [Member] | Minimum [Member]
Exercise price per share (in dollars per share)	$ 0
Warrants 2015 [Member] | Maximum [Member]
Exercise price per share (in dollars per share)	$ 243.75
Warrants 2016 [Member]
Shares, warrants (in shares) | shares	756,999
Exercise price per share (in dollars per share)	$ 4.46
Warrants 2017 [Member]
Shares, warrants (in shares) | shares	1,082,946
Warrants 2017 [Member] | Minimum [Member]
Exercise price per share (in dollars per share)	$ 1.07
Warrants 2017 [Member] | Maximum [Member]
Exercise price per share (in dollars per share)	$ 2.25
Warrants 2018 [Member]
Shares, warrants (in shares) | shares	918,375
Exercise price per share (in dollars per share)	$ 1
Stock Options 2011 [Member]
Shares, options (in shares) | shares	173
Price, options (in dollars per share)	$ 281.25
Stock Options 2012 [Member]
Shares, options (in shares) | shares	1,841
Stock Options 2012 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 131.25
Stock Options 2012 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 150
Stock Options 2013 [Member]
Shares, options (in shares) | shares	1,553
Stock Options 2013 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 148.125
Stock Options 2013 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 596.25
Stock Options 2014 [Member]
Shares, options (in shares) | shares	836
Stock Options 2014 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 162.50
Stock Options 2014 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 431.25
Stock Options 2015 [Member]
Shares, options (in shares) | shares	4,088
Stock Options 2015 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 65.75
Stock Options 2015 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 86.25
Stock Options 2016 [Member]
Shares, options (in shares) | shares	144,422
Stock Options 2016 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 2.25
Stock Options 2016 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 5.13
Stock Options 2017 [Member]
Shares, options (in shares) | shares	2,612,070
Stock Options 2017 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 1.01
Stock Options 2017 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 2.10
Stock Options 2018 [Member]
Shares, options (in shares) | shares	325,595
Stock Options 2018 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 0.97
Stock Options 2018 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 1.35

Note 4 - Notes Receivable (Deta

Note 4 - Notes Receivable (Details Textual) - USD ($)	1 Months Ended
	Mar. 31, 2018	Dec. 31, 2017	Nov. 30, 2017	Jul. 31, 2017
Advance to Helomics [Member]
Notes Receivable, Interest Rate, Stated Percentage			8.00%
Payments to Acquire Notes Receivable			$ 600,000
Advances to De Lage Landen [Member]
Payments to Acquire Notes Receivable		$ 67,512.10
CytoBioscience [Member] | Promissory Notes Receivable [Member]
Notes Receivable, Interest Rate, Stated Percentage	8.00%			8.00%
Financing Receivable, Net, Total	$ 1,112,524	$ 1,070,000
Notes Receivable, Term	2 years
Helomics Holding Corp. [Member]
Financing Receivable, Net, Total	$ 167,512.10
Share Exchange Agreement, Outstanding Receivables, Amount Converted	$ 500,000
Share Exchange Agreement, Shares Received Upon Conversion of Receivables	833,333
Share Exchange Agreement, Convertible Notes, Percent of Stock	5.00%
Investment, Ownership Percent	25.00%

Note 5 - Loss Per Share (Detail

Note 5 - Loss Per Share (Details Textual) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,950,630	1,427,558
Preferred Stock 1 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	79,246

Note 5 - Loss Per Share - Share

Note 5 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)		3 Months Ended		12 Months Ended
		Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Net loss available in basic and diluted calculation		$ (1,760,022)	$ (1,341,847)	$ (7,746,593)
Unrealized gain from marketable securities				$ (1,501)
Comprehensive (loss)		$ (1,760,022)	$ (1,341,847)
Weighted average common shares outstanding-basic (in shares)		11,383,217	6,450,967
Effect of diluted stock options, warrants and preferred stock (1) (in shares)	[1]
Loss per common share - basic and diluted (in dollars per share)		$ (0.15)	$ (0.21)
[1]	The number of shares underlying options and warrants outstanding as of March 31, 2018 and March 31, 2017 are 5,950,631 and 1,427,558 respectively. The number of shares underlying the preferred stock as of March 31, 2018 is 79,246. The effect of the shares that would be issued upon exercise of such options, warrants and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

Note 6 - Income Taxes (Details

Note 6 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			34.00%
Income Tax Expense (Benefit), Total	$ 0
Valuation Allowance Percentage	100.00%
Domestic Tax Authority [Member]
Operating Loss Carryforwards, Total	$ 36,100		$ 34,500
Operating Loss Carryforwards, Valuation Allowance, Total	7,700		7,400
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	12,400		12,200
Operating Loss Carryforwards, Valuation Allowance, Total	$ 1,000		$ 200
Scenario, Forecast [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		21.00%

Note 6 - Income Taxes - Compone

Note 6 - Income Taxes - Components of Deferred Income Taxes (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Net Operating Loss	$ 8,554,404	$ 7,393,000
Other	192,522	215,843
Total Deferred Tax Asset	8,746,926	7,608,943
Less Valuation Allowance	8,746,926	7,608,943
Net Deferred Income Taxes	$ 0	$ 0

Note 7 - Rent Obligation (Detai

Note 7 - Rent Obligation (Details Textual)	3 Months Ended
	Mar. 31, 2018USD ($)ft²	Mar. 31, 2017USD ($)
Operating Leases, Rent Expense, Total | $	$ 17,244	$ 16,895
Corporate Office, Minnesota [Member]
Lessee Leasing Arrangements Operating Leases Terms of Contract Cancellation	3 years
Area of Real Estate Property	5,773
Corporate Office, Minnesota [Member] | Office Space [Member]
Area of Real Estate Property	2,945
Corporate Office, Minnesota [Member] | Manufacturing Facility [Member]
Area of Real Estate Property	2,828

Note 7 - Rent Obligation - Rent

Note 7 - Rent Obligation - Rent Obligation (Details)	Mar. 31, 2018USD ($)
2,018	$ 29,250
2,019	40,000
2,020	42,000
2,021	$ 3,000

Note 8 - Related Party Transa40

Note 8 - Related Party Transactions (Details Textual) - USD ($)	Sep. 20, 2016	Apr. 30, 2018
Director [Member] | Subsequent Event [Member]
Related Party Transaction, Monthly Cash Payment		$ 12,000
Director [Member] | Subsequent Event [Member] | Restricted Stock Units (RSUs) [Member] | Stock Incentive Plan 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		240,000
GLG Pharma, LLC. [Member]
Stock Expected to be Issued Upon Agreement, Shares	400,000
Stock Expected to be Issued Upon Agreement, Shares, Tranche One	100,000
Stock Expected to be Issued Upon Agreement, Shares, Tranche Four	100,000
Stock Expected to be Issued Upon Agreement, Shares, Tranche Two	100,000
Stock Expected to be Issued Upon Agreement, Shares, Tranche Three	100,000

Note 9 - Retirement Savings P41

Note 9 - Retirement Savings Plan (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	100.00%		100.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	4.00%		4.00%
Defined Contribution Plan, Employer Contribution Amount	$ 11,907	$ 9,770

Note 10 - Subsequent Events (De

Note 10 - Subsequent Events (Details Textual) - USD ($)	Apr. 20, 2018	Jan. 11, 2018	Apr. 30, 2018
Helomics Holding Corp. [Member]
Stock Issued During Period, Shares, New Issues		1,100,000
Convertible Preferred Stock Held, Conversion Feature, Percent		20.00%
Subsequent Event [Member] | Helomics Holding Corp. [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	7,500,000
Director [Member] | Subsequent Event [Member]
Related Party Transaction, Monthly Cash Payment			$ 12,000
Director [Member] | Subsequent Event [Member] | Stock Incentive Plan 2012 [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			240,000